logo.png
Arch Biopartners Arranges Non-Brokered Private Placement
23. Dezember 2020 08:53 ET | Arch Biopartners
TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
10. Dezember 2020 07:27 ET | Arch Biopartners
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Veterans Affairs San Diego Healthcare System...
logo.png
Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST
07. August 2020 11:34 ET | Arch Biopartners
TORONTO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it will host a webinar on August 18, 2020 at...
logo.png
Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide
04. August 2020 08:00 ET | Arch Biopartners
TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received independent Institutional Review...
logo.png
Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.
14. Juli 2020 07:00 ET | Arch Biopartners
Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with...
logo.png
Arch Biopartners Closes Non-Brokered Private Placement
30. Juni 2020 09:21 ET | Arch Biopartners
TORONTO, June 30, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...